{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:26:46Z","timestamp":1790526406781,"version":"4.1.0"},"reference-count":43,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a rare type of B-cell Non-Hodgkin lymphoma (NHL) affecting predominantly male patients. While complete remissions following first-line treatment are frequent, most patients ultimately relapse, with a usually aggressive further disease course. The use of cytarabine-comprising induction chemotherapy and autologous stem cell transplantation, Rituximab maintenance, Bruton\u2019s tyrosine kinase (BTK) inhibitors and CAR T therapy has substantially improved survival. Still, options for patients relapsing after CAR T therapy are limited and recommendations for the treatment of these patients are lacking. We report two cases of patients with mantle cell lymphoma who relapsed after CAR T therapy and were treated with the bispecific CD20\/CD3 T cell engaging antibody glofitamab. Both patients showed marked increases of circulating CAR T cells and objective responses after glofitamab administration. Therapy was tolerated without relevant side effects in both patients. One patient completed all 12 planned cycles of glofitamab therapy and was alive and without clinical progression at the last follow-up. The second patient declined further treatment after the first cycle and succumbed to disease progression. We review the literature and investigate possible mechanisms involved in the observed responses after administration of glofitamab, such as proliferation of CAR T cells, anti-tumor effects of the bispecific antibody and the role of other possibly contributing factors. Therapy with bispecific antibodies might offer an effective and well-tolerated option for patients with mantle cell lymphoma relapsing after CAR T therapy.<\/jats:p>","DOI":"10.3390\/cells11172747","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T20:48:25Z","timestamp":1662410905000},"page":"2747","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"11","author":[{"given":"Alexander D.","family":"Heini","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-1935","authenticated-orcid":false,"given":"Naomi","family":"Porret","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-1011","authenticated-orcid":false,"given":"Gertrud","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Legros","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Stalder Zeerleder","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-0505","authenticated-orcid":false,"given":"Michael","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.leukres.2015.03.004","article-title":"CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma","volume":"39","author":"Berger","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00508-021-01948-2","article-title":"CAR T-cell therapy and critical care: A survival guide for medical emergency teams","volume":"133","author":"Messmer","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2021-145872","article-title":"Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL) Who Have Received \u22652 Prior Lines of Therapy: Pivotal Results from a Phase I\/II Study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20 \u00d7 CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-targeting t-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell Lymphoma: A phase i trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2021-148949","article-title":"Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R\/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton\u2019s Tyrosine Kinase Inhibitor (BTKi) Therapy","volume":"138","author":"Phillips","year":"2021","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rentsch, V., Seipel, K., Banz, Y., Wiedemann, G., Porret, N., and Pabst, T. (2022). Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy. Cancers, 14.","DOI":"10.3390\/cancers14102516"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exphem.2020.07.003","article-title":"Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome","volume":"88","author":"Pabst","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"112662","DOI":"10.1016\/j.jim.2019.112662","article-title":"EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets","volume":"475","author":"Grigore","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/curroncol29020065","article-title":"Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology","volume":"29","author":"Shumilov","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_19","unstructured":"Miltenyi Biotec B.V. & Co. KG (2022, July 05). CD19 CAR Detection Reagent (Biotin) Flyer. Available online: https:\/\/www.miltenyibiotec.com\/_Resources\/Persistent\/05b3a1b4dc07c7e4447e6d348428e215d591bebc\/CD19_CAR_Detection_Reagent_%28Biotin%29_flyer.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41409-022-01658-x","article-title":"Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: Real-world experience from a single tertiary care center","volume":"57","author":"Heini","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hon.62_2879","article-title":"Sakk 36\/13 - Ibrutinib Plus Bortezomib and Ibrutinib Maintenance for Relapsed and Refractory Mantle Cell Lymphoma: Final Report of a Phase I\/II Trial of the European Mcl Network","volume":"39","author":"Novak","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1182\/blood-2019-123979","article-title":"CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial","volume":"134","author":"James","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2015.64.9970","article-title":"Bispecific T-cell engagers (BiTES) as treatment of B-cell lymphoma","volume":"34","author":"Smits","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"npj Syst. Biol. Appl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ni.2050","article-title":"Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells","volume":"12","author":"Thiery","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: An emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","first-page":"E3679","article-title":"A sharp T-cell antigen receptor signaling threshold for T-cell proliferation","volume":"111","author":"Zikherman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4049\/jimmunol.1901167","article-title":"TCR Signal Strength and Antigen Affinity Regulate CD8 + Memory T Cells","volume":"205","author":"Solouki","year":"2020","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.4049\/jimmunol.1801026","article-title":"Costimulation through TLR2 Drives Polyfunctional CD8 + T Cell Responses","volume":"202","author":"Salerno","year":"2019","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40164-020-00190-2","article-title":"Engineering better chimeric antigen receptor T cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e20201966","DOI":"10.1084\/jem.20201966","article-title":"TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion","volume":"219","author":"Shakiba","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"763412","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/hon.2439_147","article-title":"Effects on the Human Immune System After Obinutuzumab Monotherapy Treatment","volume":"35","author":"Aguinaga","year":"2017","journal-title":"Hematol. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/17\/2747\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:44Z","timestamp":1760142164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/17\/2747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":43,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cells11172747"],"URL":"https:\/\/doi.org\/10.3390\/cells11172747","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}